Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 6, 1996, Pages 687-695

  Cilla Jr , Donald D ^a   Whitfield, Lloyd R ^a   Gibson, Donald M ^a   Sedman, Allen J ^a   Posvar, Edward L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ACYL COENZYME A; ADULT; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HEPTANOIC ACIDS; HUMANS; LEAST-SQUARES ANALYSIS; LINEAR MODELS; MALE; MIDDLE AGED; PYRROLES; REFERENCE VALUES;

EID: 12644301168     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90218-0     Document Type: Article

References (13)

1. Shaw MK, Sliskovic DR, Roth B, Newton R, Krause BR. Hep-G2 cells resemble fibroblasts but not primary rat hepatocytes in their response to inhibition of HMG-CoA reductase [abstract]. FASEB J 1990;4:A533.
2. Krause BR, Bousley R, Kieft K, Stanfield R, Newton RS. Atorvastatin is superior to lovastatin for lowering plasma triglycerides in experimental animals [abstract]. FASEB J 1993;7:A567.
3. Posvar EL, Radulovic LL, Cilla DD, Whitfield LR, Sedman AJ. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol 1996;36:728-31.
4. Shum YY, Huang H, Walter G, Black AE, Sekerke CS, Homan R, et al. Development and validation of an enzyme inhibition assay for quantitation of CI-981 in human plasma [abstract]. Pharm Res 1993; 10(suppl):S-415.
5. Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 1993;87[suppl III]:45-53.
6. Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: A look back and a look ahead. Can J Cardiol 1992;8:843-64.
7. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-82.
8. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn SL, Weiss SR, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128-33.
9. Pan HY, De Vault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugerman AA. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990;30:1128-35.
10. Tobert JA, Bell GD, Birtwell J, James I, Kukovetz WR, Pryor JS, et al. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, in healthy volunteers. J Clin Invest 1982;69:913-9.
11. Mehta M, editor. Physicians desk reference on CDROM. Montvale NJ: Medical Economics Data Production Company, 1993.
12. Pan HY, Funke PT, Willard DA, McKinstry DN. Pharmacokinetics, pharmacodynamics and safety of pravastatin sodium, a potent inhibitor of HMG-CoA reductase, in healthy volunteers. In: LaRosa JC, editor. New advances in the control of lipid metabolism: focus on pravastatin. Royal Society of Medicine Services international congress and symposium series No. 162, 1989:9-22.
13. Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, Dann EJ, et al. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation 1993;87[suppl III]:35-44.